obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
=== Organ transplantation === It has similar immunosuppressive properties to ciclosporin, but is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study. Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation. Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including steroids, mycophenolate, and IL-2 receptor inhibitors such as basiliximab. Dosages are titrated to target blood levels at specific times after medication administration.
=== Effects === A spasm may lead to muscle strains or tears in tendons and ligaments if the force of the spasm exceeds the tensile strength of the underlying connective tissue. This can occur with a particularly strong spasm or with weakened connective tissue.
==== Dilution effect ==== Death-penalty supporters state that the claim that pancuronium dilutes the sodium thiopental dose is erroneous. Supporters argue that pancuronium and thiopental are commonly used together in everyday surgery and that if there were a dilution effect, it would be a known drug interaction. Drug interactions are a complex topic. Simplistically, drug interactions can be classified as synergistic or inhibitory. Drug interactions can happen in two ways: directly at the place where the drug works or indirectly when the drug is processed in the liver or removed by the kidney. Pancuronium and thiopental have different sites of action, one in the brain and one at the neuromuscular junction. Since the half-life of thiopental is 11.5 hours, the metabolism of the drugs is not an issue when dealing with the short time frame in lethal injections. The only other plausible interpretation would be a direct one, or one in which the two compounds interact with each other. Supporters of the death penalty argue that this theory does not hold true. They state that even if the 100 mg of pancuronium directly prevented 500 mg of thiopental from working, sufficient thiopental to induce coma would be present for 50 hours. In addition, if this interaction did occur, then the pancuronium would be incapable of causing paralysis.
=== Pharmacokinetics === While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.
=== Humanitarian response === The Lebanon Humanitarian Fund launched its reserve allocation that includes up to US$4 million to support its partners to help aid those who have been displaced or still in conflict zones.
Sources: en.wikipedia.org
Of particular concern in nuclear waste management are two long-lived fission products, Tc-99 (half-life 220,000 years) and I-129 (half-life 15.7 million years), which dominate spent fuel radioactivity after a few thousand years. The most troublesome transuranic elements in spent fuel are Np-237 (half-life two million years) and Pu-239 (half-life 24,000 years). Nuclear waste requires sophisticated treatment and management to successfully isolate it from interacting with the biosphere. This usually necessitates treatment, followed by a long-term management strategy involving storage, disposal or transformation of the waste into a non-toxic form. Governments around the world are considering a range of waste management and disposal options, though there has been limited progress toward long-term waste management solutions.
Perhaps the best-known hypothesis involving mercury and autism involves the use of the mercury-based compound thiomersal, a preservative that has been phased out from most childhood vaccinations in developed countries including the US and EU. There is no scientific evidence for a connection between thiomersal and autism, but parental concern about a relationship between thiomersal and vaccines led to decreasing rates of childhood immunizations and increasing likelihood of disease outbreaks in the 1990s. In 1999, the U.S. Public Health Service recommended that thiomersal be removed from childhood vaccines. By 2002, the flu vaccine was the only childhood vaccine using thiomersal. The removal of thiomersal did not decrease autism rates in any country that removed thiomersal from their childhood vaccines. A causal link between thiomersal and autism has been rejected by international scientific and medical professional bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the European Medicines Agency.
=== Gold Cup runners-up and the 2001 Copa América (2000–2001) === Colombia made their first appearance at the CONCACAF Gold Cup as invited guests in 2000, beating Jamaica 1–0 through Gonzalo Martínez and losing 2–0 to Honduras in a three-team group, both matches played at the Miami Orange Bowl. In the quarter-final on 19 February they twice came from behind against the hosts the United States — Faustino Asprilla cancelling out Brian McBride and Gerardo Bedoya equalising in the 81st minute after Chris Armas had scored — to draw 2–2 after extra time, then won the shootout 2–1 in a sequence in which six of the nine attempts failed. A 2–1 semi-final win over Peru at Qualcomm Stadium followed, an own goal by Marcial Salazar and a Víctor Bonilla strike putting Colombia through before a crowd of 3,402. In the final at the Los Angeles Memorial Coliseum on 27 February, Canada won 2–0 through a Jason de Vos header in first-half stoppage time and a Carlo Corazzin penalty, before 6,197 spectators.
Infrared spectroscopy exploits the fact that molecules absorb frequencies that are characteristic of their structure. These absorptions occur at resonant frequencies, i.e. the frequency of the absorbed radiation matches the vibrational frequency. The energies are affected by the shape of the molecular potential energy surfaces, the masses of the atoms, and the associated vibronic coupling.
=== Da–Di === Jeff Dahn (born 1957), Canadian materials chemist noted for significant contributions to lithium-ion batteries John Dalton (1766–1844), British chemist, physicist and meteorologist, whose work laid the foundations of modern atomic theory and stoichiometric chemistry Marie Maynard Daly (1921–2003), American biochemist who studied the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and uptake of creatine by muscle cells Carl Peter Henrik Dam (1895–1976), Danish biochemist, winner of the 1943 Nobel Prize in Physiology or Medicine for discovering vitamin K and its role in human physiology Samuel J. Danishefsky (born 1936), American organic chemist, natural product total synthesis, 1995/6 Wolf Prize in Chemistry Raymond Davis, Jr.
Sources: en.wikipedia.org
and it is equal to 0.0065 for U-235. The value of β depends on the fissioning isotope and on the energy of the fissioning neutrons, so it is not a universal constant. Thermal fission of Pu-239 gives β ≈ 0.0021, about a third of the U-235 value, while fast fission of U-238 gives 0.0148, so the values differ by more than a factor of seven across the actinides. In a reactor, the effective β must be averaged over the fuel isotope mixture, which changes with core life. Since the bred fuels Pu-239 and U-233 have somewhat lower delayed neutron yields than U-235, in most thermal reactors the effective delayed neutron fraction decreases as the core ages. The delayed neutron fraction (DNF) is defined as:
The earlier DOx drugs like DOM and DOET were subsequently followed by DOB, which was developed by Shulgin and colleagues like Claudio Naranjo, in 1971, and by DOI, DOC, and a few other analogues, which were developed by another research group, in 1973. After this, numerous other DOx drugs were synthesized and characterized, both by Shulgin and other scientists. Following its discovery, DOI has become widely used in scientific research in the study of the serotonin 5-HT2 receptors.
The fall of the Han dynasty was followed by an age of fragmentation and several centuries of disunity amid warfare among rival kingdoms. There was a brief period of prosperity under the native Han Chinese dynasty known as the Jin (266–420 AD), although protracted struggles within the ruling house of Sima (司馬) sparked off a protracted period of fragmentation, rebellion by immigrant tribes that served as slaves and indentured servants, and extended non-native rule.
Np(III) or Np3+ exists as hydrated complexes in acidic solutions, Np(H2O)3+n. It is a dark blue-purple and is analogous to its lighter congener, the pink rare-earth ion Pm3+. In the presence of oxygen, it is quickly oxidized to Np(IV) unless strong reducing agents are also present. Nevertheless, it is the second-least easily hydrolyzed neptunium ion in water, forming the NpOH2+ ion. Np3+ is the predominant neptunium ion in solutions of pH 4–5.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.